Nifty Pharma up 11% in a month: gainers, laggards 2026

A sharp pharma rebound in a weak headline market

The Nifty Pharma index has surged nearly 11% over the past month, standing out in a market where the Nifty 50 declined 3.6% over the same period. The move has been broad-based, with all but two constituents posting positive returns in the last month. The rally matters because it highlights a clear rotation into defensives during a softer tape for benchmark equities. It also shows that leadership within pharma has not been uniform, with select names contributing most of the upside. In parallel, market commentary has pointed to mid-tier pharmaceutical stocks doing much of the “heavy lifting” rather than the largest names. Taken together, the data paints a picture of sector-specific strength amid uneven market breadth.

One-month performance: Nifty Pharma beats Nifty 50

Over the past month, the relative performance gap between Nifty Pharma and the Nifty 50 has been notable. A nearly 11% rise for the sector index against a 3.6% decline in the headline index implies investors have actively preferred healthcare exposure. The breadth has also been supportive, since only two stocks in the Nifty Pharma index delivered negative returns in the period. That breadth is important because narrow rallies can fade quickly when they rely on one or two heavyweights. Here, gains were spread across multiple tiers of the sector. Even so, the distribution of returns shows a clear cluster of outsized winners at the top.

Gainers and laggards: who moved the most

Gland Pharma led the pack with a rally of more than 27% over the past month. Laurus Labs and Biocon followed, gaining in the 21% to 23% range. A second group of stocks advanced between 10% and 15%, including Ajanta Pharma, Cipla, Mankind Pharma, Granules India, Sun Pharmaceutical Industries, Zydus Lifesciences, and JB Chemicals & Pharmaceuticals. Another set of names climbed between 6% and 10%: Torrent Pharmaceuticals, Divi’s Laboratories, Dr Reddy’s Laboratories, Abbott India, Ipca Laboratories, Aurobindo Pharma, Natco Pharma, and Glenmark Pharmaceuticals. The only laggards in the index were Lupin, down 0.57%, and Alkem Laboratories, down 2.91%. This split indicates that the month’s momentum was strong, but not universal.

Mid-tier pharma in focus, per market commentary

Alongside the month-on-month index data, market commentary suggested that “some stocks” have been outperformers and may be the source of alpha. The commentary cited Aurobindo as “up 20 times” and trading at 18 times one-year forward, while Glenmark was described as up around 10% and Lupin up around 9% at 23 times forward. JB Chemicals was described as up around 8.7%, and Torrent Pharma as up around 6%. The same commentary argued that mid-tier pharmaceutical names are doing much of the heavy lifting. It added that pharma may not be leading the rally “right at this point in time,” but may be protecting portfolios in a weak market. While these points reflect market positioning views rather than audited results, they align directionally with the sector’s relative outperformance over the month.

March 2026 snapshot: select pharma fundamentals on record

The data set also provided a March 2026 snapshot of operating and valuation metrics for several listed pharma companies. The following table reproduces the figures shown for the companies where rows were visible.

The mixed 2026 YTD picture behind the one-month surge

The one-month rally contrasts with the sector’s year-to-date numbers cited in the data. Against the Nifty 50’s rise of 6.21% year-to-date, the Nifty Pharma index has slipped 4.57%, according to ACE Equity data referenced in the text. Several pharma stocks were highlighted as notable laggards on a YTD basis: Natco Pharma down 37.85%, Ipca Labs down 22.43%, Aurobindo Pharma down 17.99%, and Sun Pharma down 14.30%. Other laggards listed include Lupin (down 13.25%) and Dr Reddy’s (down 5.17%). This divergence suggests the latest month’s strength has followed a period of weakness for parts of the pack. It also helps explain why the month’s rebound is being watched closely, particularly for signs of durable rotation rather than a short-covering bounce.

What analysts are watching within pharma

A specific stock-level view was also included in the text. Ravi Singh said Glenmark has “stood out with strong momentum,” while Zydus, Torrent, and Abbott India “look better placed.” The same remark cautioned that “the rest may take longer to recover” until headwinds such as pricing and a regulatory overhang ease. This kind of framing is consistent with the dispersion visible in returns across the index. It also underscores that investors are separating perceived near-term momentum from broader sector recovery. Importantly, these remarks were presented as positioning views tied to market conditions, not as forecasts with quantified outcomes.

Brokerage action elsewhere adds to the day’s market context

Separate from pharma, multiple brokerage calls were listed across sectors, reflecting a mixed stance on valuations and growth. Bernstein initiated coverage on Eternal and Swiggy with ‘Outperform’ ratings and target prices of Rs 390 and Rs 570, respectively. Bernstein also initiated ‘underperform’ ratings on Waaree Energies and Premier Energies, setting target prices of Rs 1,902 and Rs 693 and citing potential downside of more than 17% and 21.6%, respectively. Titan Company was noted to have slipped almost a percent to Rs 3,627 in morning deals on Tuesday, August 26, even as Bernstein initiated coverage with an outperform rating and a target of Rs 4,200 per share. The text also mentioned Jefferies maintaining “Buy” ratings for IndiGo and Indian Hotels, and a range of calls including a “reduce” on Tata Technologies by Axis Capital and a “buy” initiation on 360 One by UBS.

Market Impact

The most immediate market impact visible in the data is relative performance: pharma outperformed while the Nifty 50 fell over the month. That type of divergence often affects sector allocation decisions for investors who manage exposure across indices. Within the sector, the rise was not concentrated in a single stock, since most constituents posted gains and several names logged double-digit returns. At the same time, the YTD underperformance of Nifty Pharma versus the Nifty 50 indicates that the sector has not been a consistent leader through 2026 so far. This mix can influence how investors treat the move, either as a rebound within a lagging sector or as the start of a sustained rotation.

Analysis: why the move matters for investors

The data points to two key takeaways that investors typically track: breadth and leadership. Breadth was strong over the past month, with only Lupin and Alkem in the red, which supports the case that the move was sector-wide rather than isolated. Leadership, however, leaned on a handful of large gainers such as Gland Pharma, Laurus Labs, and Biocon, alongside a long list of mid-range winners. The additional commentary about alpha shifting from large-caps to mid-tier names reinforces the leadership narrative, even though the specific “up 20 times” phrasing around Aurobindo appears as-is in the text. Finally, the contrast between month-on-month strength and YTD weakness suggests investors are responding to more recent catalysts, flows, or positioning rather than long-running sector tailwinds that are visible in the YTD index numbers.

Conclusion

Nifty Pharma’s nearly 11% rise in a month, against a 3.6% fall in the Nifty 50, has put the sector back on investors’ radar. The gains were broad, led by Gland Pharma and supported by multiple stocks delivering mid-to-high single digit and double-digit returns, while Lupin and Alkem were the only laggards. But the YTD picture remains weaker for the sector index versus the broader market, with several named stocks still down sharply for the year. Market participants are also watching whether momentum continues to concentrate in select names, as highlighted by commentary that mid-tier stocks are doing much of the heavy lifting. The next key datapoint for investors will be whether the sector sustains this relative outperformance as broader market conditions evolve.